The key finding was that that for people on treatment and with high CD4 cell counts, life expectancy was only a few years lower than the general population, regardless of when they had started treatment. People who started treatment after 2015 have a slightly higher life expectancy than those who started ART before 2015. However, CD4 cell count has the strongest influence on life expectancy.